Popular search terms:
Search Results
12 results found-
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
https://www.csl.com/news/2020/20201009-first-patient-enrolled-in-nih-covid19-phase-3-trial -
• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.
https://www.csl.com/news/2020/20200730-perreault-urges-plasma-donations-at-white-house-roundtable -
Stage gate approval process •
https://www.csl.com/-/media/csl/documents/cfo-presentation-at-macquarie-conference-may-2018.pdf -
Driven by Our Promise TM Progress Through Stage Gates in 2018
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2018.pdf -
10 Global Progress Through Stage Gates in 2017
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Progress through Stage Gates in 2013
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2013.pdf -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity 8 expansions, yield improvements, new packages and sizes for all registered products Global Progress Through Stage Gates in 2016
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Progress through Stage Gates in 2014
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2014.pdf -
Partnered Projects 9 #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Global Progress through Stage Gates in 2015
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2015.pdf -
Prior to Takeda, Dr Yamada was President of the Bill & Melinda Gates Foundation Global Health Program and prior to that was Chairman of Research and Development at GlaxoSmithKline.
https://www.csl.com/-/media/csl/documents/february-2019-csl-prospectus_final.pdf